Bio-Path Holdings, Inc. (OTC BB: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that an abstract entitled, “Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)” has been accepted for a poster presentation at the 53 rd Annual Meeting of the American Society of Hematology (ASH) to be held December 10 to 13, 2011 in San Diego, California. The ASH Annual Meeting is the premier event for physicians and healthcare researchers involved in hematology to meet to learn about the latest developments to treat blood diseases.
The abstract contains a summary of the results of the first cohort in the ongoing Phase I clinical trial of Bio-Path’s lead drug candidate Liposomal Grb-2 being evaluated in patients with blood cancers. The lead author for the abstract is Jorge Cortes, M.D., Professor of Leukemia at The University of Texas MD Anderson Cancer Center and Principal Investigator for the Phase I clinical trial.
“We are extremely pleased and honored that this abstract has been accepted for presentation at this important meeting of physicians and researchers in the field of hematology,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path. “The abstract accepted for presentation is a summary of results from a very early stage in our Phase I program. We believe the inclusion of these early results at the ASH annual meeting indicates that the reviewers see the potential importance of our drug candidate Liposomal Grb-2 as a new and novel way of treating AML, CML, ALL and MDS blood cancers.”
Bio-Path is developing a neutral lipid-based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules), a delivery technology that forms microscopic-sized vehicles to safely deliver these drugs to their intended target cancer cells.